Cytokinetics (CYTK) Non-Current Assets (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Non-Current Assets of $434.0 million for Q1 2026, up 40.91% year-over-year from $308.0 million in Q1 2025, and down 14.49% quarter-over-quarter from $507.6 million in Q4 2025.
Cytokinetics (CYTK) Non-Current Assets (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Non-Current Assets for 17 consecutive years, with $434.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 40.91% year-over-year to $434.0 million; the TTM figure through Mar 2026 stood at $1.7 billion (up 17.94% YoY), while the FY2025 annual figure was $507.6 million, up 72.8% from the prior year.
- Non-Current Assets fell to $434.0 million in Q1 2026 per CYTK's latest filing, from $507.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $507.6 million in Q4 2025 and bottomed at $169.4 million in Q1 2024.
- Historically, Non-Current Assets has averaged $292.7 million across 5 years, with a median of $232.7 million in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Assets slumped 42.37% — and 2024, when it soared 135.86%.
- Cytokinetics' Non-Current Assets stood at $219.6 million in 2022, then dropped by 10.62% to $196.3 million in 2023, then jumped by 49.66% to $293.7 million in 2024, then surged by 72.8% to $507.6 million in 2025, then slipped by 14.49% to $434.0 million in 2026.
- Business Quant data shows CYTK's Non-Current Assets at $434.0 million in Q1 2026, $507.6 million in Q4 2025, and $459.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 716.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 716.06 Mn |
| Mar 31, 2026 | 434.01 Mn |
| Dec 31, 2025 | 507.56 Mn |
| Sep 30, 2025 | 459.21 Mn |
| Jun 30, 2025 | 339.09 Mn |
| Mar 31, 2025 | 308.00 Mn |
| Dec 31, 2024 | 293.73 Mn |
| Sep 30, 2024 | 417.46 Mn |
| Jun 30, 2024 | 455.98 Mn |
| Mar 31, 2024 | 169.38 Mn |
| Dec 31, 2023 | 196.27 Mn |
| Sep 30, 2023 | 179.20 Mn |
| Jun 30, 2023 | 193.32 Mn |
| Mar 31, 2023 | 209.19 Mn |
| Dec 31, 2022 | 219.59 Mn |
| Sep 30, 2022 | 191.69 Mn |
| Jun 30, 2022 | 169.47 Mn |
| Mar 31, 2022 | 232.73 Mn |
| Dec 31, 2021 | 305.65 Mn |
| Sep 30, 2021 | 332.60 Mn |